BMN-351 in Muscular Dystrophy, Duchenne: NCT07573631 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 11 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Enrolling by invitation
Recruitment status
18
Planned enrollment
2031-12-01
Primary-completion proxy
Executive view
NCT07573631 evaluates BMN-351 in Muscular Dystrophy, Duchenne. The disclosed sponsor is BioMarin Pharmaceutical, Inc., the design is Interventional, and the geographic footprint is Netherlands, Turkey, United Kingdom, Italy, Spain. The first listed primary endpoint is To assess the long-term safety and tolerability of BMN 351 in participants with DMD, assessed over Through study completion, at least 1 year.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07573631 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Muscular Dystrophy, Duchenne landscape. Drug & Asset MCP drug_fetch was queried for BMN-351, while Company & Deal Intelligence MCP organization_fetch was queried for BioMarin Pharmaceutical, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07573631 | BMN-351 | Phase 2 / Enrolling by invitation | BioMarin Pharmaceutical, Inc. | Netherlands, Turkey, United Kingdom, Italy, Spain | To assess the long-term safety and tolerability of BMN 351 in participants with DMD Through study completion, at least 1 year | 2031-12-01 |
| NCT07608432 | Zeleciment Rostudirsen | Phase 3 / Recruiting | Dyne Therapeutics, Inc. | United States | Rise From Floor (RFF) velocity Baseline, Week 73 | 2030-12-01 |
| NCT07587242 | Delpacibart zotadirsen | Phase 3 / Recruiting | Avidity Biosciences, Inc. | Belgium, United Kingdom, Italy, France, Germany, Spain | Change from Baseline in Time to Rise (TTR) Velocity at Week 54 Baseline, Week 54 | 2029-05-01 |
| NCT07542314 | Delandistrogene moxeparvovec | Phase 4 / Not yet recruiting | Sarepta Therapeutics, Inc. | United States | Cohort 1: Number of Participants with ALI 12 weeks | 2027-08-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07573631 is a Phase 2, enrolling by invitation study with 18 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “To assess the long-term safety and tolerability of BMN 351 in participants with DMD” over “Through study completion, at least 1 year.” The retrieved endpoint description is: The safety and tolerability of BMN 351 will be assessed based on the incidence of adverse and serious adverse events..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 18 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Muscular Dystrophy, Duchenne. These records do not establish direct evidence for NCT07573631 unless the registration number matches.
Vamorolone for Duchenne Muscular Dystrophy
Phase 2; n=133; TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028); TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028) Source: https://pubmed.ncbi.nlm.nih.gov/42202243/
Lowering pre-existing immunity to adeno-associated virus-based gene therapy: Pre treatment with imlifidase or plasmapheresis prior to administration of delandistrogene moxeparvove…
Phase 1; n=8; Micro-dystrophin Expression(Week 12) = 21.5 % ( 0.96 - 42.03); Micro-dystrophin Expression(Week 12) = 1.72 % ( 1.46 - 2.11) Source: https://download.asgct.org/2026ASGCTAbstractPublication.pdf
Family experience data with delandistrogene moxeparvovec gene therapy treatment for Duchenne muscular dystrophy.
Not Applicable; n=31; Improvement in at least one of the most impactful symptoms = 96.0 % Source: https://download.asgct.org/2026ASGCTAbstractPublication.pdf
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “BMN-351.” The report therefore avoids inferring modality, target or global development stage from the name alone.
No exact Company & Deal Intelligence profile was returned for BioMarin Pharmaceutical, Inc.. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether BMN-351 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07573631
Protocol source: https://clinicaltrials.gov/study/NCT07573631
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 11 September 2026.
BMN-351 in Muscular Dystrophy, Duchenne is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes To assess the long-term safety and tolerability of BMN 351 in participants with DMD and 2031-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
